Commonwealth Bank of Australia raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 253,548 shares of the biopharmaceutical company’s stock after buying an additional 40,150 shares during the quarter. Commonwealth Bank of Australia’s holdings in Gilead Sciences were worth $17,945,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,400 shares in the last quarter. Penserra Capital Management LLC increased its holdings in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares in the last quarter. American Beacon Advisors Inc. bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $143,000. Sterling Investment Advisors Ltd. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $184,000. Finally, Washington Trust Bank increased its holdings in shares of Gilead Sciences by 24.8% during the second quarter. Washington Trust Bank now owns 2,767 shares of the biopharmaceutical company’s stock valued at $196,000 after acquiring an additional 550 shares in the last quarter. 74.62% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $71.15 on Wednesday. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $92,920.00, a PE ratio of 7.60, a PEG ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.75 EPS. sell-side analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.92%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
In related news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total transaction of $3,950,000.00. Following the transaction, the executive vice president now directly owns 113,237 shares in the company, valued at approximately $8,945,723. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The disclosure for this sale can be found here. Insiders have sold a total of 446,819 shares of company stock worth $36,269,486 over the last quarter. Corporate insiders own 1.30% of the company’s stock.
GILD has been the subject of several recent research reports. Zacks Investment Research downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. BMO Capital Markets restated a “hold” rating and set a $72.00 price objective on shares of Gilead Sciences in a report on Friday, July 21st. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Leerink Swann restated a “hold” rating and set a $74.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 25th. Finally, Robert W. Baird restated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a report on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $84.87.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.